Liposomal Doxorubicin (CaelyxR) in Symptomatic Androgen-independent Prostate Cancer (AIPC): Delayed Response and Flare Phenomenon Should be Considered

Author： Fosså Sophie D.   Vaage Sigmund   Letocha Henry   Iversen Jon   Risberg Terje   Johannessen Dag C.   Paus Elisabeth   Smedsrud Trond  

Publisher： Informa Healthcare

ISSN： 0036-5599

Source： Scandinavian Journal of Urology and Nephrology, Vol.36, Iss.1, 2002-01, pp. : 34-39

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A.   Pace C.M.   Lam P.M.   Roehrborn C.G.  

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer

By Guimaraes T.   Bento M.J.   Pinho T.   Guedes d.C.R.   Pinto F.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 159-159

Elsevier

Access to resources Recommend Favorite

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

By Vaishampayan U.   Fontana J.   Du W.   Hussain M.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1050-1054

Elsevier

Access to resources Recommend Favorite

Acid phosphatase: defining a role in androgen-independent prostate cancer

By Steineck G.   Kelly W.K.   Mazumdar M.   Vlamis V.   Schwartz M.   Scher H.I.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 719-726

Elsevier

Access to resources Recommend Favorite

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era

By Oefelein M.G.   Ricchiuti V.S.   Conrad P.W.   Goldman H.   Bodner D.   Resnick M.I.   Seftel A.  

Urology, Vol. 60, Iss. 1, 2002-07 ,pp. : 120-124

Elsevier

Access to resources Recommend Favorite